Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression disease BEFREE Pathological, immunohistochemical, and amplification refractory mutation system (ARMS) assay examinations of ovarian specimen suggested the expression of metastatic lung adenocarcinoma with wt EGFR. 28816950 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression disease BEFREE The aim of the present study was to investigate the associations between ERα/ERβ expression and EGFR mutational status and response to TKI treatment in metastatic lung adenocarcinoma. 30013628 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.030 AlteredExpression disease BEFREE Fibulin-2 was abundant in the extracellular matrix of human lung adenocarcinomas and was highly expressed in tumor cell lines derived from mice that develop metastatic lung adenocarcinoma from co-expression of mutant K-ras and p53. 23785517 2013
Entrez Id: 2625
Gene Symbol: GATA3
GATA3
0.010 AlteredExpression disease BEFREE Metastatic lung adenocarcinoma in the adrenal gland had occasional (36%) expression, while metastatic clear cell renal cell carcinoma in the adrenal gland did not express GATA3. 28374498 2017
Entrez Id: 2100
Gene Symbol: ESR2
ESR2
0.010 AlteredExpression disease BEFREE The aim of the present study was to investigate the associations between ERα/ERβ expression and EGFR mutational status and response to TKI treatment in metastatic lung adenocarcinoma. 30013628 2018
Entrez Id: 26085
Gene Symbol: KLK13
KLK13
0.010 AlteredExpression disease BEFREE Here, we provide mechanistic evidence showing that the expression of KLK13, one of the most recently identified family members, is significantly up-regulated in metastatic lung adenocarcinoma. 21596022 2011
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.010 AlteredExpression disease BEFREE The aim of the present study was to investigate the associations between ERα/ERβ expression and EGFR mutational status and response to TKI treatment in metastatic lung adenocarcinoma. 30013628 2018
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
0.010 AlteredExpression disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 8091
Gene Symbol: HMGA2
HMGA2
0.010 AlteredExpression disease BEFREE Hmga2 is highly expressed in metastatic lung adenocarcinoma, in which it contributes to cancer progression and metastasis. 24305048 2014
Entrez Id: 2199
Gene Symbol: FBLN2
FBLN2
0.010 AlteredExpression disease BEFREE Fibulin-2 was abundant in the extracellular matrix of human lung adenocarcinomas and was highly expressed in tumor cell lines derived from mice that develop metastatic lung adenocarcinoma from co-expression of mutant K-ras and p53. 23785517 2013
Entrez Id: 6285
Gene Symbol: S100B
S100B
0.010 AlteredExpression disease BEFREE We previously reported that S100B was highly expressed in PC14/B, a specific brain metastatic lung adenocarcinoma cell line, which suggests that it is associated with brain metastasis of lung cancer. 21861268 2011
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure. 21920622 2011
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE Combined, these findings define a novel transcriptional network regulating oncogenic EGFR signaling and identify a class of FDA-approved drugs as capable of restoring chemosensitivity to anti-EGFR-based therapy for the treatment of metastatic lung adenocarcinoma. 22653055 2012
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE Presence of anaplastic lymphoma kinase (ALK) rearrangement is an indication for crizotinib in the treatment of patients with advanced or metastatic lung adenocarcinoma. 28118634 2017
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE A 45-year-old Korean female with ALK-rearranged metastatic lung adenocarcinoma underwent ceritinib treatment and exhibited a partial response, until she developed organizing pneumonia resembling disease progression. 30075548 2018
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. 27393517 2016
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE We describe a case of lichenoid drug eruption (LDE) that appeared 4 weeks after initiation of treatment with crizotinib in a 61-year-old man with ALK-positive metastatic lung adenocarcinoma. 30657798 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.040 Biomarker disease BEFREE Here, we sought to characterize tumor proteome and phosphoproteome changes by longitudinal, prospective collection of tumor tissue from an exceptional responder lung adenocarcinoma patient who survived with metastatic lung adenocarcinoma for over seven years while undergoing HER2-directed therapy in combination with chemotherapy. 30617155 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.040 Biomarker disease BEFREE EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies. 29175303 2017
Entrez Id: 8030
Gene Symbol: CCDC6
CCDC6
0.020 Biomarker disease BEFREE Multiplex reverse transcription-polymerase chain reaction (RT-PCR) was used to detect KIF5B-RET and CCDC6-RET fusions from specimens of malignant pleural effusion (MPE) in patients with metastatic lung adenocarcinoma. 25773866 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.020 Biomarker disease BEFREE Multiplex reverse transcription-polymerase chain reaction (RT-PCR) was used to detect KIF5B-RET and CCDC6-RET fusions from specimens of malignant pleural effusion (MPE) in patients with metastatic lung adenocarcinoma. 25773866 2015
Entrez Id: 59
Gene Symbol: ACTA2
ACTA2
0.010 Biomarker disease BEFREE Therefore, ACTA2 could be a promising prognostic biomarker and/or therapeutic target for metastatic lung adenocarcinoma. 23995859 2013
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.010 Biomarker disease BEFREE We evaluated the diagnostic accuracy and interpathologist agreement of two anti-ROS1 IHC clones, SP384 (Ventana, Tucson, Arizona) and D4D6 (Cell Signaling, Danvers, Massachusetts), in a training cohort of 51 positive ROS1 FISH LUAD cases, and then in a large validation cohort of 714 consecutive cases of LUAD from six routine molecular pathology platforms. 30999109 2019
Entrez Id: 94025
Gene Symbol: MUC16
MUC16
0.010 Biomarker disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 3880
Gene Symbol: KRT19
KRT19
0.010 Biomarker disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019